Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.

Rodriguez BJ, Córdoba GD, Aranda AG, Álvarez M, Vicioso L, Pérez CL, Hernando C, Bermejo B, Parreño AJ, Lluch A, Ryder MB, Jones FS, Fredebohm J, Holtrup F, Queipo-Ortuño MI, Alba E.

J Clin Med. 2019 Aug 7;8(8). pii: E1183. doi: 10.3390/jcm8081183.

2.

Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project.

Torregrosa MD, Escudero MJ, Paredero I, Carrasco E, Bermejo B, Gavila J, García-Saenz J, Santaballa A, Martínez P, Llombart A, Andrés R, Batista N, Fernández A, Antón A, Seguí M, Gonzalez S, Ruiz A; GEICAM, the Spanish Breast Cancer Group.

Clin Transl Oncol. 2019 Aug 5. doi: 10.1007/s12094-019-02189-6. [Epub ahead of print]

PMID:
31385227
3.

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A.

Clin Transl Oncol. 2019 Jun 15. doi: 10.1007/s12094-019-02145-4. [Epub ahead of print]

PMID:
31203575
4.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
5.

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.

Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM.

Breast Cancer Res Treat. 2019 Aug;177(1):115-125. doi: 10.1007/s10549-019-05296-8. Epub 2019 May 31.

PMID:
31152327
6.

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.

Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, de la Peña L, Xu N, Wongchenko M, Shi Z, Singel SM, Isakoff SJ.

Ann Oncol. 2019 May 30. pii: mdz177. doi: 10.1093/annonc/mdz177. [Epub ahead of print]

PMID:
31147675
7.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
8.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P.

Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y.

9.

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator.

Martínez MT, Oltra SS, Peña-Chilet M, Alonso E, Hernando C, Burgues O, Chirivella I, Bermejo B, Lluch A, Ribas G.

Breast Cancer (Auckl). 2019 Feb 20;13:1178223419828766. doi: 10.1177/1178223419828766. eCollection 2019.

10.

Breast cancer in pregnant patients: A review of the literature.

Martínez MT, Bermejo B, Hernando C, Gambardella V, Cejalvo JM, Lluch A.

Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:222-227. doi: 10.1016/j.ejogrb.2018.04.029. Epub 2018 Apr 23. Review.

PMID:
29728277
11.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I.

JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

12.

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.

Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647.

PMID:
29045543
13.

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart MJ, Von Minckwitz G, Baselga J, Loi S.

Eur J Cancer. 2017 Nov;85:133-145. doi: 10.1016/j.ejca.2017.08.020. Epub 2017 Sep 17.

14.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

15.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

16.

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.

Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.

PMID:
28238593
17.

Physical activity and breast cancer risk by pathological subtype.

Lope V, Martín M, Castelló A, Casla S, Ruiz A, Baena-Cañada JM, Casas AM, Calvo L, Bermejo B, Muñoz M, Ramos M, de Juan-Ferré A, Jara C, Antón A, Jimeno MÁ, Lluch A, Antolín S, García-Sáenz JÁ, Estévez P, Arriola-Arellano E, Gavilá J, Pérez-Gómez B, Carrasco E, Pollán M; GEICAM, the Spanish Breast Cancer Group.

Gynecol Oncol. 2017 Mar;144(3):577-585. doi: 10.1016/j.ygyno.2016.12.014. Epub 2017 Jan 3.

PMID:
28057355
18.

A survey-based analysis on endoscopic quality indicators compliance among Spanish endoscopists.

Fernández-Urien I, Argüelles-Arias F, Alonso-Aguirre PA, Júdez J, Bermejo B.

Rev Esp Enferm Dig. 2017 Jan;109(1):33-48. doi: 10.17235/reed.2016.4705/2016.

19.

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A.

Breast Cancer Res Treat. 2016 Nov;160(1):69-77. Epub 2016 Sep 14.

PMID:
27628192
20.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, García-Saenz JA, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simon S, Carrato A, Lopez-Alonso A, Escudero MJ, Campo R, Carrasco E, Palacios J, Mulero F, Colomer R.

Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.

21.

Complementary clinical effects of red complex bacteria on generalized periodontitis in a caucasian population.

Lanza E, Magan-Fernandez A, Bermejo B, de Rojas J, Marfil-Alvarez R, Mesa F.

Oral Dis. 2016 Jul;22(5):430-7. doi: 10.1111/odi.12471. Epub 2016 Apr 26.

PMID:
26948988
22.

Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy.

Rico M, Martínez E, Pellejero S, Bermejo B, Navarrete P, Barrado M, Campo M, Mañeru F, Villafranca E, Aristu J.

Clin Transl Oncol. 2016 Oct;18(10):1011-8. doi: 10.1007/s12094-015-1475-8. Epub 2016 Jan 12.

PMID:
26758718
23.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.

Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4.

24.

SEOM clinical guidelines in early-stage breast cancer 2015.

Garcia-Saenz JA, Bermejo B, Estevez LG, Palomo AG, Gonzalez-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez CA, Ciruelos E.

Clin Transl Oncol. 2015 Dec;17(12):939-45. doi: 10.1007/s12094-015-1427-3. Epub 2015 Oct 26.

25.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.

Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo B, Martín M, Albanell J, Lluch A.

Crit Rev Oncol Hematol. 2016 Jan;97:96-106. doi: 10.1016/j.critrevonc.2015.08.011. Epub 2015 Aug 11. Review.

PMID:
26318092
26.

[Comparison of intracranial meningioma outcome scales in operated patients older than 65 years old. Our experience between 2002-2012 and a literature review].

Díaz J, Carballares J, Zabalo G, Bermejo B, Zazpe I, Portillo E.

Neurocirugia (Astur). 2016 Jan-Feb;27(1):2-9. doi: 10.1016/j.neucir.2015.04.003. Epub 2015 May 29. Review. Spanish.

PMID:
26028583
27.

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.

Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; EpiGEICAM Researchers.

PLoS One. 2015 May 15;10(5):e0126096. doi: 10.1371/journal.pone.0126096. eCollection 2015.

28.

The emotional experience of people with intellectual disability: an analysis using the international affective pictures system.

Bermejo BG, Mateos PM, Sánchez-Mateos JD.

Am J Intellect Dev Disabil. 2014 Jul;119(4):371-84. doi: 10.1352/1944-7558-119.4.371.

PMID:
25007300
29.

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.

Pérez-Fidalgo JA, Bermejo B, Chirivella I, Martínez MT, González I, Cejalvo JM, Catoira I, Martínez P, Contel E, Lluch A.

Clin Transl Oncol. 2014 Sep;16(9):814-22. doi: 10.1007/s12094-013-1153-7. Epub 2014 Feb 15.

30.

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J.

Clin Cancer Res. 2014 Jan 15;20(2):511-21. doi: 10.1158/1078-0432.CCR-13-0239.

31.

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM.

Breast. 2013 Oct;22(5):974-9. doi: 10.1016/j.breast.2013.05.014. Epub 2013 Jun 25.

PMID:
23809906
32.

Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.

Rodrigues P, Furriol J, Bermejo B, Chaves FJ, Lluch A, Eroles P.

Int J Mol Sci. 2012 Dec 5;13(12):16500-13. doi: 10.3390/ijms131216500.

33.

Cross-modal plasticity in deaf child cochlear implant candidates assessed using visual and somatosensory evoked potentials.

Charroó-Ruíz LE, Picó T, Pérez-Abalo MC, Hernández Mdel C, Bermejo S, Bermejo B, Álvarez B, Paz AS, Rodríguez U, Sevila M, Martínez Y, Galán L.

MEDICC Rev. 2013 Jan;15(1):16-22.

34.

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, Carrasco E, Lluch A; GEICAM.

Ann Oncol. 2012 Dec;23(12):3069-74. doi: 10.1093/annonc/mds132. Epub 2012 Jun 6.

PMID:
22674146
35.

Cross-modal plasticity in Cuban visually-impaired child cochlear implant candidates: topography of somatosensory evoked potentials.

Charroó-Ruíz LE, Pérez-Abalo MC, Hernández MC, Alvarez B, Bermejo B, Bermejo S, Galán L, Díaz-Comas L.

MEDICC Rev. 2012 Apr;14(2):23-9. Erratum in: MEDICC Rev. 2012 Apr;14(2):29.

36.

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁ, Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F.

J Clin Oncol. 2012 May 1;30(13):1484-91. doi: 10.1200/JCO.2011.36.7771. Epub 2012 Mar 12.

PMID:
22412143
37.

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.

Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM, Wildiers H, Torres A, Provencher L, Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang L, Richel DJ.

Ann Oncol. 2012 Jul;23(7):1780-8. doi: 10.1093/annonc/mdr519. Epub 2011 Nov 4.

PMID:
22056854
38.

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

Pérez-Fidalgo JA, Pimentel P, Caballero A, Bermejo B, Barrera JA, Burgues O, Martinez-Ruiz F, Chirivella I, Bosch A, Martínez-Agulló A, Lluch A.

Breast. 2011 Dec;20(6):548-54. doi: 10.1016/j.breast.2011.06.005. Epub 2011 Aug 3.

PMID:
21816613
39.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

Ann Oncol. 2012 Mar;23(3):625-31. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6.

PMID:
21652577
40.

Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.

Anton A, Lluch A, Casado A, Provencio M, Muñoz M, Lao J, Bermejo B, Paules AB, Gayo J, Martin M.

Anticancer Res. 2010 Jun;30(6):2255-61.

PMID:
20651377
41.

Mechanisms of resistance to hormonal treatment in breast cancer.

Eroles P, Bosch A, Bermejo B, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):246-52. doi: 10.1007/s12094-010-0500-1. Review.

PMID:
20462833
42.

[Clinical interventions on the major vascular risk factors (RIVANA study)].

Amezqueta C, Bermejo B, Guembe MJ, Artázcoz MT, Viñes JJ.

An Sist Sanit Navar. 2009 Sep-Dec;32(3):351-62. Spanish.

43.

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J.

Ann Oncol. 2010 Jul;21(7):1442-7. doi: 10.1093/annonc/mdp536. Epub 2009 Nov 25.

PMID:
19940004
44.

Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories.

Blancas I, Gómez FJ, Bermejo B, Hennessy BT, Chirivella I, Magro A, Caballero A, Ferrer J, Valero V, Lluch A.

Clin Breast Cancer. 2009 Nov;9(4):231-6. doi: 10.3816/CBC.2009.n.039.

PMID:
19933078
45.

Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.

Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, Chirivella I, Guzman C, Lluch A.

Breast Cancer Res Treat. 2010 Feb;120(1):245-51. doi: 10.1007/s10549-009-0426-x. Epub 2009 Jul 3.

PMID:
19575291
46.

[On quality assurance in anesthesia].

Perepérez M, Rodríguez del Rio JM, Bermejo B, Catalán J.

Rev Esp Anestesiol Reanim. 2008 Nov;55(9):587-9. Spanish. No abstract available.

PMID:
19086735
47.

Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain).

Pérez-Fidalgo JA, Miranda J, Chirivella I, Ibáñez J, Bermejo B, Pons C, Melchor I, Santaballa A, Martínez-Ruiz F, Lluch A, Salas D.

Clin Transl Oncol. 2008 Nov;10(11):745-52.

PMID:
19015071
48.

Indium determination in different environmental materials by electrothermal atomic absorption spectrometry with Amberlite XAD-2 coated with 1-(2-pyridylazo)-2-naphthol.

Martínez A NC, Barrera AB, Bermejo B P.

Talanta. 2005 Apr 30;66(3):646-52. doi: 10.1016/j.talanta.2004.12.002. Epub 2005 Jan 12.

PMID:
18970033
49.

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.

Chirivella I, Bermejo B, Insa A, Pérez-Fidalgo A, Magro A, Rosello S, García-Garre E, Martín P, Bosch A, Lluch A.

Breast Cancer Res Treat. 2009 Apr;114(3):479-84. doi: 10.1007/s10549-008-0018-1. Epub 2008 May 8.

PMID:
18463977
50.

Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.

Blancas I, García-Puche JL, Bermejo B, Hanrahan EO, Monteagudo C, Martínez-Agulló A, Rouzier R, Hennessy BT, Valero V, Lluch A.

Ann Oncol. 2006 Nov;17(11):1644-9. Epub 2006 Jul 27.

PMID:
16873428

Supplemental Content

Loading ...
Support Center